IL283614B1 - Methods for selective in vivo expansion of gamma delta T-cell populations and preparations thereof - Google Patents

Methods for selective in vivo expansion of gamma delta T-cell populations and preparations thereof

Info

Publication number
IL283614B1
IL283614B1 IL283614A IL28361421A IL283614B1 IL 283614 B1 IL283614 B1 IL 283614B1 IL 283614 A IL283614 A IL 283614A IL 28361421 A IL28361421 A IL 28361421A IL 283614 B1 IL283614 B1 IL 283614B1
Authority
IL
Israel
Prior art keywords
selective
compositions
methods
cell populations
vivo expansion
Prior art date
Application number
IL283614A
Other languages
English (en)
Hebrew (he)
Other versions
IL283614A (en
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of IL283614A publication Critical patent/IL283614A/en
Publication of IL283614B1 publication Critical patent/IL283614B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL283614A 2018-12-03 2021-06-01 Methods for selective in vivo expansion of gamma delta T-cell populations and preparations thereof IL283614B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862774817P 2018-12-03 2018-12-03
PCT/US2019/064319 WO2020117862A1 (en) 2018-12-03 2019-12-03 Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof

Publications (2)

Publication Number Publication Date
IL283614A IL283614A (en) 2021-07-29
IL283614B1 true IL283614B1 (en) 2026-03-01

Family

ID=69005987

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283614A IL283614B1 (en) 2018-12-03 2021-06-01 Methods for selective in vivo expansion of gamma delta T-cell populations and preparations thereof

Country Status (12)

Country Link
US (1) US20220218747A1 (enExample)
EP (1) EP3890757A1 (enExample)
JP (2) JP2022510387A (enExample)
KR (1) KR20210099615A (enExample)
CN (1) CN113518624A (enExample)
AU (1) AU2019394877A1 (enExample)
BR (1) BR112021010804A2 (enExample)
CA (1) CA3126896A1 (enExample)
IL (1) IL283614B1 (enExample)
MX (1) MX2021006503A (enExample)
SG (1) SG11202105860QA (enExample)
WO (1) WO2020117862A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006547A (es) * 2019-12-03 2022-08-19 Adicet Bio Inc Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
CN115746131B (zh) * 2022-08-01 2025-09-30 杭州旭科生物技术有限公司 抗天然类风湿因子rf的单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
WO2017197347A1 (en) * 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
MX336846B (es) 2010-01-22 2016-02-03 Sangamo Biosciences Inc Alteracion genomica dirigida.
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
JP2016501013A (ja) * 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
CN104651308A (zh) * 2013-11-22 2015-05-27 深圳先进技术研究院 一种用磷酸盐扩增γδT细胞的方法及其应用
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
MX2020005005A (es) 2017-11-15 2020-08-27 Adicet Bio Inc Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
WO2017197347A1 (en) * 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUA, FANG, ET AL., POTENTIAL REGULATORY ROLE OF IN VITRO-EXPANDED V?1 T CELLS FROM HUMAN PERIPHERAL BLOOD., 31 December 2013 (2013-12-31) *

Also Published As

Publication number Publication date
WO2020117862A1 (en) 2020-06-11
US20220218747A1 (en) 2022-07-14
KR20210099615A (ko) 2021-08-12
CN113518624A (zh) 2021-10-19
SG11202105860QA (en) 2021-07-29
CA3126896A1 (en) 2020-06-11
JP2025063054A (ja) 2025-04-15
MX2021006503A (es) 2021-08-05
BR112021010804A2 (pt) 2021-11-16
AU2019394877A1 (en) 2021-06-17
EP3890757A1 (en) 2021-10-13
IL283614A (en) 2021-07-29
JP2022510387A (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
ZA201808140B (en) Methods for selective expansion of gd t-cell populations and compositions thereof
IL287248A (en) Methods and preparations for editing RN" A
IL282191A (en) Methods and preparations for editing RN" A
IL319114A (en) Expansion of gamma delta T cells, compositions and methods for use thereof
IL281424A (en) Microbiota restoration treatment preparations and production methods
SG11202103571XA (en) Compositions and methods for immunotherapy
SG11202008659TA (en) Cartyrin compositions and methods for use
SG11202101814RA (en) Compositions of cxcr4 inhibitors and methods of preparation and use
SG10201913562VA (en) Hsp90 inhibitor oral formulations and related methods
IL283614B1 (en) Methods for selective in vivo expansion of gamma delta T-cell populations and preparations thereof
SG11202001095UA (en) Diverting agent and method of filling fracture in well using the same
SG11202106053SA (en) Compositions and methods for immunotherapy
EP3645020A4 (en) COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPY
IL273754A (en) Fortified oral taxane preparations and methods
IL274640A (en) Methods for the selective expansion of delta 3 gamma-delta T-cell populations and preparations thereof
IL282533A (en) Oligosaccharide preparations and methods of using them
IL287797A (en) Oligosaccharide preparations and methods of use
IL271596A (en) Preparations for administering drugs and methods of using them
EP4448514A4 (en) TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES
EP3304041A4 (en) Methods of assessing cellular breast samples and compositions for use in practicing the same
IL274563A (en) Methods of use and preparations containing dolaglutide
IL290325A (en) Biopharmaceutical preparations and related methods
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
PL3580267T3 (pl) Prasowane kompozycje cząstek, sposoby ich wytwarzania i ich zastosowanie
GB202009592D0 (en) Formulations of tie-2 activators and methods of use thereof